PressFebruary 17, 2026 Compass hits primary endpoint in second Phase 3 psilocybin trial, giving it two positive pivotal studies
PressFebruary 9, 2026 Clearmind reports additional positive safety data for CMND-100 in alcohol use disorder
PressFebruary 4, 2026 Trump administration officials strip Compass psilocybin from FDA fast-track voucher list
PressJanuary 26, 2026 Optimi Health completes first 2026 production run of MDMA and psilocybin capsules
PressJanuary 12, 2026 MindMed unveils full rebrand as Definium Therapeutics, spotlighting late-stage LSD pipeline
PressDecember 11, 2025 AtaiBeckley granted new U.S. patent for oral R-MDMA candidate EMP-01, extending exclusivity to 2043
PressDecember 10, 2025 PharmAla completes release testing on first Australian-made LaNeo MDMA capsules
PressDecember 5, 2025 New Mexico's Medical Psilocybin Advisory Board convenes, eyes accelerated launch
PressDecember 4, 2025 Bipartisan 'Freedom to Heal Act' would open Right to Try access to psilocybin and MDMA
PressDecember 2, 2025 FDA accepts NRx's ANDA for preservative-free IV ketamine KETAFREE with July 2026 goal date
